ライフサイエンスコーパス: receptor type

1 ansmitter release, cell firing, and dopamine-receptor type.

2 n spike timing, dopamine level, and dopamine receptor type.

3 cell firing, and identification of dopamine receptor type.

4 nnervation to this sense organ employs other receptor types.

5 across species, despite stark differences in receptor types.

6 e similar affinities for different nicotinic receptor types.

7 tors and also as versatile ligands for other receptor types.

8 y tracts, with similar distributions of both receptor types.

9 dentified one important gene, angiotensin II receptor type 1 (AGTR1), in the Ca2+/AT-IIR/alpha-AR sig

10 in minutes by pharmacological angiotensin-II receptor type 1 (AT1 R) blockade.

11 l evidence indicates that the angiotensin II receptor type 1 (AT1 R) is inherently mechanosensitive a

12 model of PTSD and the selective angiotensin receptor type 1 (AT1) antagonist losartan, we investigat

13 nd identified telmisartan, an angiotensin II receptor type 1 (AT1R) blocker, as a potent inhibitor of

14 estin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), stimulates acute catecholamine s

15 r calcium release mediated by angiotensin II receptor type 1 (AT1R).

16 or signalling through BMEC AT2R, HSCP Ang-II receptor type 1 (AT1R)/AT2R or HSC/P RhoA, but not by in

17 Some inverse agonists of cannabinoid receptor type 1 (CB1) have been demonstrated to be anore

18 d neuroprotective efficacies via cannabinoid receptor type 1 (CB1) or type 2 (CB2) or via peroxisome

19 the relationship between in vivo cannabinoid receptor type 1 (CB1) receptor availability in the amygd

20 nist/inverse agonist activity at cannabinoid receptor type 1 (CB1R) and inhibitory effect on inducibl

21 The cannabinoid receptor type 1 (CB1R) colocalized with TRPV1:tdTomato e

22 OX-A receptor type 1 (OX-1R) and cannabinoid receptor type 1 (CB1R) on the plasma membrane.

23 ha2A-adrenergic receptor, GABAB, cannabinoid receptor type 1 (CB1R), and dopamine receptor type 2.

24 aptic transmission in the PL via cannabinoid receptor type 1 (CB1R)- and 2-arachidonoylglycerol-depen

25 ne receptor type 4 (CXCR4) and C-C chemokine receptor type 1 (CCR1), which are the receptors of SDF-1

26 erozoite surface interacting with complement receptor type 1 (CR1, CD35) on the erythrocyte membrane.

27 r blockade of corticotropin-releasing factor receptor type 1 (CRF-R1) could prevent the emergence of

28 ide driven by corticotropin-releasing factor receptor type 1 (CRF1) potentiation of the anandamide ca

29 n between the corticotropin releasing factor receptor type 1 (CRF1R) and its native 40-mer peptide li

30 f the class B corticotropin-releasing factor receptor type 1 (CRF1R) with two peptide agonists and th

31 Corticotropin-releasing factor receptor type 1 (CRFR1) is involved in activation of the

32 however, concerning the contribution of CRF receptor type 1 (CRFR1) to this effect and whether CRF w

33 ound that CRH, through activation of the CRH receptor type 1 (CRHR1), evokes a rapid induction of the

34 edium spiny neurons expressing dopamine (DA) receptor type 1 (D1-MSNs) and type 2 (D2-MSNs) of the NA

35 mushroom spines of MSNs expressing dopamine receptor type 1 (D1-MSNs).

36 ablation of this receptor-type, but not FGF receptor type 1 (FGFR1), resulted in attenuation of myel

37 We report that mature IL-1 signaling at IL-1 receptor type 1 (IL-1R1) is maintained at pH 6.2, but th

38 Both Toll-like receptor 2 (TLR2) and IL-1 receptor type 1 (IL-1r1) upstream of MyD88 have been imp

39 rs, IL-1 receptor accessory protein and IL-1 receptor type 1 (IL-1R1), and enhanced sensitivity to IL

40 pertussis toxin administration leads to IL-1 receptor type 1 (IL-1R1)-dependent IL-1beta expression b

41 how that mice deficient in the interleukin-1 receptor type 1 (Il1r1(-/-)) have reduced numbers of neu

42 The lysophosphatidic acid receptor type 1 (LPA1) is 1 of 6 known receptors of the

43 X-A)-expressing inputs and express both OX-A receptor type 1 (OX-1R) and cannabinoid receptor type 1

44 Here we show that signaling at orexin receptor type 1 (OxR1) in the VTA is required for morphi

45 ed the effects of BPA and TBBPA on ryanodine receptor type 1 (RyR1), dihydropyridine receptor (DHPR),

46 m (SR) Ca(2+) release channel, the ryanodine receptor type 1 (RyR1).

47 red the binding of the capsid to transferrin receptor type 1 (TfR), particularly during virus dissoci

48 (VEGFR), vascular endothelial growth factor receptor type 1 (VEGFR1), vascular endothelial growth fa

49 his study reveals that LPA signaling via LPA receptor type 1 activation causes demyelination and func

50 rarenal angiotensinogen production and ANGII receptor type 1 activation that are associated with incr

51 pocampal slices, and hippocampal cannabinoid receptor type 1 and brain-derived neurotrophic factor (B

52 RAP; IL1R3) is a coreceptor of interleukin-1 receptor type 1 and has been found upregulated on CML st

53 7c inhibited both the expression of TGF-beta receptor type 1 and the response to TGF-beta1.

54 can be reversed acutely by an angiotensin-II receptor type 1 antagonist.

55 553Leu]) in the inositol 1,4,5-trisphosphate receptor type 1 gene (ITPR1).

56 show that the corticotropin-releasing factor receptor type 1 has a specific monomer/dimer equilibrium

57 complex with transforming growth factor beta receptor type 1 kinase domain were determined by X-ray c

58 nsporter-1, glucose transporter-2, and taste receptor type 1 member 2 (T1R2) transcripts.

59 -129/Sv-4A11(+/+), and blockade of the ANGII receptor type 1 with losartan normalizes BP.

60 at central cannabinoid receptor (cannabinoid receptor type 1) agonists decrease the power of neural o

61 oexcitation is independent of angiotensin II receptor type 1, oxytocin, ionotropic glutamate and GABA

62 , adenylate cyclase activating polypeptide 1 receptor type 1, was associated with individual differen

63 ntibody antagonist of metabotropic glutamate receptor type 1.

64 ished for the corticotropin-releasing factor receptor type 1.

65 OP mutation [c.617G>A, p.R206H] of Activin A Receptor, type 1 (ACVR1) and that affects the same intra

66 we found ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) as a direct novel target of HIF2alpha

67 , association of PKCalpha and angiotensin-II receptor, type 1, with Cav-3 was disrupted in the hypert

68 incipal neurons were dependent on muscarinic receptors type 1, engaging different intracellular mecha

69 therapeutic targets include the cannabinoid receptors, type 1 and 2, as well as biosynthetic and cat

70 ia endothelin receptor type A (ETAR) and Ang receptor type-1 (AT1R) activation are implicated in PAH

71 Cannabinoid receptor type-1 (CB1) is known to have a substantial imp

72 Cannabinoid receptor type-1 (CB1) plays a crucial role in controllin

73 ion of NAc FSIs that express the cannabinoid receptor type-1 (CB1).

74 Here we show that muscarinic receptor type-1 (Chrm1) signaling in the hypothalamus pr

75 baseline Ca(2+)-dependent response to AngII receptor type-1 activation by AngII.

76 s have shown that AngII binding to the AngII receptor type-1 elicits baseline-dependent regulation of

77 or associated with RSD did not occur in IL-1 receptor type-1 knock-out (IL-1R1(KO)) mice.

78 pathogenic protein tyrosine phosphatase, non-receptor type 11 (PTPN11) variant and variants of uncert

79 Here, we demonstrate that PTP non-receptor type 12 (PTPN12) protects cells against aberran

80 in receptor, the growth hormone secretagogue receptor type 1a (GHS-R1a), in VP neurons caused the den

81 al ligand of the growth hormone secretagogue receptor type 1a (GHS-R1a), is mainly secreted from the

82 Oral administration of the serotonin receptor type 1A agonist buspirone prior to levodopa red

83 pport the development of selective serotonin receptor type 1A agonists for use as antidyskinetic agen

84 KEY POINTS: The angiotensin II receptor type 1b (AT1 Rb ) is the primary sensor of intr

85 se-related microRNAs targeting the activin A receptor type 1C (ACVR1C), a component of the transformi

86 growth factor beta (47%) and angiotensin II receptor type 2 (132%), 27% less elastin as well as conc

87 Expression of bone morphogenetic protein receptor type 2 (BMPR2) and its target, collagen IV, sig

88 in the gene coding bone morphogenic protein receptor type 2 (BMPR2) and related genes.

89 gene encoding the bone morphogenetic protein receptor type 2 (BMPR2) are the commonest genetic cause

90 mutations in the bone morphogenetic protein receptor type 2 (BMPR2) gene and patients with idiopathi

91 e mutation in the bone morphogenetic protein receptor type 2 (BMPR2) gene, right ventricle (RV) dysfu

92 l cycle control and bone morphogenic protein receptor type 2 (BMPR2) signaling, and reversed vascular

93 stream to Fyn, MCP1 stimulated C-C chemokine receptor type 2 (CCR2) and Gi/o and inhibition of either

94 C-C chemokine receptor type 2 (CCR2) and its ligands (CCL2 and CCL7) w

95 A comparison of the MCP-1/C-C chemokine receptor type 2 (CCR2) chemokine system between the two

96 tients with a special focus on C-C chemokine receptor type 2 (CCR2) expressions on classical Mo.

97 C-C chemokine receptor type 2 (CCR2) is expressed by active hepatic st

98 or pharmacologic inhibition of CC chemokine receptor type 2 (CCR2) reduced macrophage (MP) infiltrat

99 40-B, a selective inhibitor of C-C chemokine receptor type 2 (CCR2), could further reduce albuminuria

100 generated MDSC were expressed C-C chemokine receptor type 2 (CCR2), which was enhanced by exposure t

101 Purpose To characterize a chemokine receptor type 2 (CCR2)-binding peptide adapted for use a

102 A C-C chemokine receptor type 2 (CCR2)-positive macrophage subpopulation

103 ivated C3b, which are ligands for complement receptor type 2 (CR2/CD21), the aim of the current study

104 sponse, while corticotropin-releasing factor receptor type 2 (CRFR2) has been suggested to mediate te

105 expression of corticotropin-releasing factor receptor type 2 (CRFR2) to be associated with post-traum

106 e etiology of SZ and coding for the dopamine receptor type 2 (D2).

107 naptic responses in MSNs expressing dopamine receptor type 2 (D2-MSNs).

108 Here, we show that FGF receptor type 2 (FGFR2) is highly enriched at the parano

109 Formyl-peptide receptor type 2 (FPR2; also called ALX because it is the

110 patients with human epidermal growth factor receptor type 2 (HER-2)-expressing malignancy.

111 one subtypes), human epidermal growth factor receptor type 2 (HER2 subtype), tumor size, and tumor gr

112 patients) and human epidermal growth factor receptor type 2 (HER2) (in 15,418 patients in trials wit

113 Because the human epidermal growth factor receptor type 2 (HER2) is overexpressed in breast and ov

114 The human growth factor receptor type 2 (HER2) is overexpressed in breast as wel

115 sion status of human epidermal growth factor receptor type 2 (HER2) predicts the response of HER2-tar

116 receptor (HR)/ human epidermal growth factor receptor type 2 (HER2) status.

117 ide therapy of human epidermal growth factor receptor type 2 (HER2)-expressing tumors.

118 Mice bearing human epidermal growth factor receptor type 2 (HER2)-overexpressing tumors were inject

119 node-negative, human epidermal growth factor receptor type 2 (HER2)-positive breast cancers, because

120 rated that the human epidermal growth factor receptor type 2 (HER2)-targeting ADAPT6 labeled with rad

121 agonist (IL-1Ra) and the decoy receptor IL-1 receptor type 2 (IL-1R2).

122 Interleukin-1 receptor type 2 (IL1R2) acts as a decoy receptor of exog

123 Compounds acting via the neurotensin receptor type 2 (NTS2) are known to be active in animal

124 erent forms of AF, have implicated ryanodine receptor type 2 (RyR2) dysfunction and enhanced spontane

125 reticulum (SR) Ca(2+) leak via the ryanodine receptor type 2 (RyR2) has been observed as a source of

126 hought to be due to an increase in ryanodine receptor type 2 (RyR2) open probability by direct oxidat

127 Selective antagonism of somatostatin receptor type 2 (SSTR2) normalizes glucagon and corticos

128 In this study, we analyzed TGFbeta receptor type 2 (TGFBR2) expression and correlated it wi

129 by Tregs was fully abolished by blocking TNF receptor type 2 (TNFR2) or by using TNF-deficient donor

130 d role of vascular endothelial growth factor receptor type 2 (VEGFR2) in the regulation of gingival v

131 ffects on vascular endothelial growth factor receptor type 2 (VEGFR2) phosphorylation, tumor volume,

132 (VEGFR1), vascular endothelial growth factor receptor type 2 (VEGFR2), and vascular endothelial growt

133 1 receptor blockade diminished C-C chemokine receptor type 2 [CCR2(neg) (Ly6C(lo))] monocytes, attenu

134 of immunoprecipitated JMC proteins ryanodine receptor type 2 and junctophilin-2 (JPH2) followed by ma

135 of immunoprecipitated JMC proteins ryanodine receptor type 2 and junctophilin-2 (JPH2) followed by ma

136 a(2+) leakage through destabilized ryanodine receptor type 2 Ca(2+) release channels.

137 The ryanodine receptor type 2 channel protein is modulated by various

138 lt of increased activity of mutant ryanodine receptor type 2 channels, sarcoplasmic reticulum Ca(2+)

139 +) release events from hyperactive ryanodine receptor type 2 channels.

140 The PKA activation destabilized ryanodine receptor type 2 channels.

141 Deficiency of the protein induces ryanodine receptor type 2 dysfunction by a mechanism that attenuat

142 mutations in the bone morphogenetic protein receptor type 2 gene (BMPR2).

143 sed PKA signaling in turn promotes ryanodine receptor type 2 hyperphosphorylation, which contributes

144 tor-a and vascular endothelial growth factor receptor type 2 in the infarcted region.

145 lar similarity to bone morphogenetic protein receptor type 2 mutation-associated heritable pulmonary

146 tional activity, secretion of VEGF, and VEGF receptor type 2 phosphorylation and down-regulated PC2 p

147 potential involvement of increased ryanodine receptor type 2 phosphorylation in the pathogenesis of h

148 is area, the functional effects of ryanodine receptor type 2 phosphorylation remain disputed.

149 Cardiac ryanodine receptor type 2 plays a key role in excitation-contracti

150 The C-C chemokine receptor type 2 protein (CCR2) functions in directing mo

151 ing miRYR2-U10 in correcting RyR2 (Ryanodine Receptor type 2 protein) function after in vivo delivery

152 ha2A-adrenergic receptor, GABAB, or dopamine receptor type 2 receptors did not reveal any interaction

153 is caused by impairment of vasopressin (VP) receptor type 2 signaling.

154 Y720)-sensitive manner and use C-C chemokine receptor type 2 to accumulate in inflamed skin where the

155 Expression of cannabinoid receptor Type 2 was reported in osteoblasts and osteocla

156 compatibility complex II/C-C motif chemokine receptor type 2) macrophages expressed higher levels of

157 l glands, it increased mRNAs of melanocortin receptor type 2, steroidogenic acute regulatory protein

158 nds to CB1 more selectively than cannabinoid receptor type 2, with a Ki value of 220 nM.

159 g PIDs are mediated by inositol triphosphate receptor type 2-dependent (IP3R2-dependent) release from

160 tages of Huntington's disease, when dopamine receptor type 2-expressing striatal medium spiny neurons

161 ts angiogenesis through activation of the DA receptor type 2.

162 abinoid receptor type 1 (CB1R), and dopamine receptor type 2.

163 Ca(2+)-cycling proteins including ryanodine receptor type 2.

164 9.43E-07) and neurotrophic tyrosine kinase, receptor, type 2 [NTRK2, a brain-derived neurotrophic fa

165 s718314) in the inositol 1,4,5-trisphosphate receptor, type 2 gene (ITPR2) was found to interact with

166 Cannabinoid receptors type 2 (CB2) represent a target with increasin

167 mCD16(+)) monocytes, and their C-C chemokine receptor type-2 (CCR2) expression were quantified by flo

168 This activity occurred within dopamine receptor type-2 (D2R)-expressing cells in the nucleus ac

169 oplasmic reticulum Ca(2+)-leak via ryanodine receptor type-2 (RyR2) contributes to the pathogenesis o

170 TGF-beta receptor type-2 (TGFBR2) is the ligand-binding receptor

171 ncreased, and PKA sites Ser2808 in ryanodine receptor type-2, Ser16 in phospholamban, and Ser23/24 in

172 (IL23R) and protein tyrosine phosphatase non-receptor type 22 (PTPN22) pathways.

173 RESISTANCE1-LIKE/REGULATORY COMPONENT OF ABA RECEPTORS, TYPE 2C PROTEIN PHOSPHATASE Sucrose non-ferme

174 e (SS) and HCV, presence of anti- muscarinic receptor type 3 (M3R) antibodies in SS, the role that M3

175 Wild-type and MC receptor type 3 (MC3)-null mice of different ages were a

176 pression of the neurotrophin tyrosine kinase receptor type 3 (NTRK3) in both PAND patients and a tran

177 FR2), and vascular endothelial growth factor receptor type 3 (VEGFR3).

178 b/CD18 beta2 integrin heterodimer complement receptor type 3/Mac-1.

179 lude C17orf104, inositol 1,4,5-trisphosphate receptor, type 3 (ITPR3), and discoidin domain receptor

180 vation, and the combination of C-C chemokine receptor type 4 (CCR4) chemokine receptors and beta1 and

181 mokine receptor type 5 and chemokine-related receptor type 4 (CCR5 and CXCR4) on peripheral blood mon

182 mpaired by the inhibitors of C-X-C chemokine receptor type 4 (CXCR4) and C-C chemokine receptor type

183 Moreover, Plg regulated C-X-C chemokine receptor type 4 (CXCR4) expression in stem cells in vivo

184 monstrate high expression of C-X-C chemokine receptor type 4 (CXCR4) mutation in Waldenstrom macroglo

185 The SDF-1alpha/C-X-C receptor type 4 (CXCR4) pathway directly promotes hepati

186 The C-X-C chemokine receptor type 4 (CXCR4) plays a crucial role in modulati

187 ted with very high levels of C-X-C chemokine receptor type 4 (CXCR4) production.

188 The human protein tyrosine phosphatase non-receptor type 4 (PTPN4) prevents cell death induction in

189 stromal cell-derived 1 alpha receptor (C-X-C receptor type 4 or CXCR4) using AMD3100 prevented the po

190 sensitive stromal-derived factor-1/chemokine receptor type 4 signaling revealed greater functional de

191 en and elastin staining, and C-X-C chemokine receptor type 4, nuclear factor kappa beta, and tartrate

192 nstrated that ORM1 can bind to C-C chemokine receptor type 5 (CCR5) on muscle cells and deletion of t

193 r prechallenge levels of CD4(+)C-C chemokine receptor type 5 (CCR5)(+)HLA-DR(+) T cells in the rectal

194 H program, as exemplified by C-X-C chemokine receptor type 5 (CXCR5) upregulation.

195 opulation is enriched with a C-X-C chemokine receptor type 5 (CXCR5)(+)CD4(+) TFH precursor phenotype

196 global reductions in metabotropic glutamate receptor type 5 (mGluR5) binding in smokers and recent e

197 cluding a decrease in metabotropic glutamate receptor type 5 (mGluR5) expression and reduced glutamat

198 ht that activation of metabotropic glutamate receptor type 5 (mGluR5) on interneuron spines leads to

199 n of an antagonist of metabotropic glutamate receptor type 5 (mGluR5) or its downstream signaling mol

200 rentiation 4 (CD4) and coreceptors chemokine receptor type 5 and chemokine-related receptor type 4 (C

201 Individuals homozygous for the C-C chemokine receptor type 5 gene with 32-bp deletions (CCR5Delta32)

202 motif) ligand 5 that binds to C-C chemokine receptor type 5 on BCCs and BCCs secrete cytokine CSF1 t

203 While frequencies of foreskin C-C chemokine receptor type 5(+) (CCR5(+)) T cells, T regulatory cells

204 c CD8 T cells express CXCR5 (C-X-C chemokine receptor type 5, a chemokine receptor required for homin

205 igands for HIV entry coreceptor CC chemokine receptor type 5.

206 ger nucleases (ZFNs) targeting C-C chemokine receptor type 5.

207 nd 16 (CXCL16) that binds to C-X-C chemokine receptor type 6 (CXCR6) on MSCs and MSCs secrete chemoki

208 CC chemokine receptor type 9 (CCR9) activation by CCL25 plays a key r

209 djacent endothelial cells via paracrine EDN1 receptor type A (EDNRA) activation.

210 iated with increased glomerular endothelin-1 receptor type A (Ednra) expression and increased circula

211 The endothelin receptor type A (EDNRA) signaling pathway is essential f

212 T) 1 and angiotensin (Ang) II via endothelin receptor type A (ETAR) and Ang receptor type-1 (AT1R) ac

213 d cells, we further identified the scavenger receptor type A member I (SR-AI) to be a macrophage-spec

214 darusentan (DAR), which potently blocks Edn1 receptor type A, could benefit cell engraftment.

215 the signaling receptor, natriuretic peptide receptor type A, to the clearance receptor, nprc, was in

216 ants influencing expression of EPHA2 (Ephrin-receptor Type-A2), a tyrosine kinase receptor that has b

217 S/heparin and NRP-1 may dictate the specific receptor type activated by VEGF and ultimately determine

218 esult not possible from activation of either receptor type alone.

219 cally important to identify the specific FGF receptor type and its downstream signaling molecules in

220 s, which restricts the diffusion of multiple receptor types and bound cargo.

221 hanisms determining agonist efficacy at this receptor type are not yet fully understood.

222 We find that specific receptor types are expressed by distinct combinations of

223 These cells highly expressed endothelin receptor type B (ETB(R)) and Jagged1, a Notch1 receptor

224 helin 3 (EDN3), its receptor (the endothelin receptor type B [EDNRB]), and the transcription factors

225 Antagonists of endothelin receptor type B also inhibited remyelination of experime

226 encing, we discovered that EDNRB (Endothelin receptor type B) is a candidate gene involved in HA adap

227 lar pathway whereby membrane-bound scavenger receptor type B-1 (SR-B1) in parent cells becomes incorp

228 Scavenger receptor type B-1 (SR-B1), found in lipid rafts, is a re

229 al HDLs, biomimetic HDL-NPs target scavenger receptor type B-1, a high-affinity HDL receptor expresse

230 Conditional ablation of this receptor-type, but not FGF receptor type 1 (FGFR1), resu

231 Surprisingly, five of the six UV receptor types contain the same visual pigment.

232 ogical manipulation to reveal the individual receptor type contributions, we find that m2 muscarinic

233 efore, blocking detrimental activity of both receptor types could be therapeutically beneficial.

234 a CNV region in protein tyrosine phosphatase receptor type D (PTPRD) with significant association wit

235 t abundant nAChR type in the brain, and this receptor type exists in alternate (alpha4beta2)2alpha4 a

236 sor candidates, protein tyrosine phosphatase receptor type F (PTPRF).

237 In particular, protein tyrosine phosphatase, receptor type, F (PTPRF) may serve as a biomarker linkin

238 Protein-tyrosine phosphatase receptor type G (RPTPgamma/PTPRG) interacts in vitro wit

239 H) and the peroxisome proliferator-activated receptor type gamma (PPARgamma).

240 by focusing on protein tyrosine phosphatase receptor type gamma (PTPRG), a tyrosine phosphatase high

241 cient trafficking of a sensory receptor, the receptor-type guanylate cyclase GCY-9, to cilia in chemo

242 sized that disrupting the cognate type I IFN receptor (type I IFN alpha/beta receptor [IFNAR]) to int

243 in homolog 1 (DMH1) or CRISPR/Cas9 activin A receptor type I (ACVR1) knockout in OPCs.

244 , because macrophages deficient in IFN-alpha receptor type I (IFNAR1) are highly resistant to necropt

245 mat targeting the insulin-like growth factor receptor type I (IGF-1R) and the epidermal growth factor

246 tokine family that signals through the IL-20 receptor type I (IL-20Ralpha:IL-20Rbeta), is a cytokine

247 ited reduced transforming growth factor-beta receptor type I (TGF-beta RI) expression that did not im

248 o an increase in the expression of the AngII receptor type I a and activation of signaling at 100-fol

249 factor kappaB signaling, and increases AngII receptor type I a expression, thus potentiating AngII si

250 signaling and increases expression of AngII receptor type I a.

251 ich in turn down-regulated sequentially IL-1 receptor type I and Sema3A expression through Erk/Jnk-de

252 Par2 expression to repress sequentially IL-1 receptor type I and Sema3A expression.

253 , and this effect was abolished by histamine receptor type I antagonist.

254 The TGF-beta receptor type I kinase inhibitor SB431542 [4-(4-(benzo[d

255 Interleukin-1 receptor type I knockout mice, which display braked immu

256 signaling, including the IL-6 receptor, IL-1 receptor type I, and IL-1 receptor type II.

257 orphogenic protein receptor kinase activin A receptor, type I (ACVR1), and the subsequent reduction o

258 ities by engaging two distinct classes of Fc receptors (type I and type II) on the basis of the two d

259 for binding to intact, functional ryanodine receptors type I (RyR1) and II (RyR2) from skeletal and

260 Strikingly, we found that IFN-alpha/beta receptor (type-I IFN receptor) was expressed by primary

261 s contain somatic mutations in the activin A receptor type IB (ACVR1B) gene, indicating that ACVR1B c

262 (Type III) cell transmitter, but not ATP, a Receptor (Type II) cell transmitter.

263 ls provides negative paracrine feedback onto Receptor (Type II) cells by activating 5-HT1A receptors,

264 In contrast, Receptor (Type II) taste cells rarely (4%) responded to

265 gene encoding the bone morphogenetic protein receptor type II (BMPR2) are the commonest genetic cause

266 rk discovery that bone morphogenetic protein receptor type II (BMPR2) mutations cause the majority of

267 ate cellular responses by binding to TGFbeta receptor type II (TbetaRII) and type I (TbetaRI) serine/

268 It was reported that TNF receptor type II signaling, which has the capacity to st

269 ZEB1, Twist, transforming growth factor-beta receptor type II, and vimentin, and aberrant E-cadherin

270 Inactivation of only the TGF-beta receptor type II, Tgfbr2, in the mouse liver (Tgfbr2(LKO

271 L-6 receptor, IL-1 receptor type I, and IL-1 receptor type II.

272 murine ortholog RAP-011) acts as an activin receptor type IIA ligand trap, increasing hemoglobin and

273 to investigate effects of a modified activin receptor type IIB (ActRIIB) ligand trap (RAP-536) that i

274 ng the extracellular domain of human activin receptor type IIB (ActRIIB) modified to reduce activin b

275 We recently reported that an activin receptor type IIB inhibitor produced hypertrophy of type

276 ability of the muscles to respond to activin receptor type IIB inhibitor treatment correlated with tr

277 Activin receptor type IIB inhibitor treatment of Mtm1 p.R69C ani

278 jor internalisation route for many different receptor types in mammalian cells.

279 ine phosphatase protein tyrosine phosphatase receptor type J (PTPRJ), a known extracellular signal-re

280 ecific receptor states, rather than specific receptor types, may be a viable strategy for future drug

281 milar region on all three traditional opioid receptor types (micro-OR, delta-OR, and kappa-OR).

282 of the antibodies, fate of the internalized receptors, type of neurons affected, and whether neurons

283 ing networks where information from numerous receptor types passes through a small set of signaling p

284 conditions remains incompletely understood, receptor type protein tyrosine phosphatase alpha (PTP-al

285 Mutations of PTPRD, a receptor-type protein tyrosine phosphatase regulating ce

286 Further, we identify a receptor type-protein tyrosine phosphatase alpha-Src fam

287 Osteoclasts express the receptor-type PTP alpha (RPTPa), which is absent from po

288 ase (STEP), and protein-tyrosine phosphatase receptor type R (PTPRR).

289 fear, and anxiety, and the specific cell and receptor types responsible is an active area of investig

290 e transferrin receptor and several glutamate receptor types, resulting in their appearance in the axo

291 The mRNA probes for the three receptor types showed differential distribution but also

292 itivities of L and M cones were, on average, receptor-type specific, but individual cone thresholds v

293 zebrafish single cell RGCs were treated with receptor-type-specific antagonists and, respectively, wi

294 Our data indicate a rapid, receptor-type-specific, two-step binding and activation

295 ll sizes to have a large number of olfactory receptor types, to maintain olfactory precision in their

296 l methodology to study the signaling role of receptor type tyrosine phosphatases and found that activ

297 among those the catalytically inactive, non-receptor-type tyrosine phosphatase PTPN23/HD-PTP.

298 bit increased PSD-95 and erbB4 and decreased receptor-type tyrosine-protein phosphatase-alpha (RPTPal

299 postsynaptic partners, the neurotransmitter receptor type used to receive input from presynaptic neu

300 ng the reach of new medicine design to novel receptor types with potential therapeutic value.